Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucitanib in Advanced/Metastatic Lung Cancer With FGF, VEGF, or PDGF Alterations
NCT02109016Phase 2Terminated
- Sponsor
- Clovis Oncology
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of lucitanib in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Clovis Oncology. Started Apr 2014; status: terminated.
02
Drugs
lucitanib
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02109016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109016.